GeneDx Holdings Corp.
WGS
Positions held
Your positionsWGS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- GeneDx Holdings Corp. operates in the growing diagnostics and research sector, which is expected to expand as personalized medicine and genetic testing gain traction.
- Revenue increased by 12% compared to the prior quarter, reaching $114 million.
- Gross margin improved to 68.4%, up from 66.7% in the previous quarter.
- The company has a high debt-to-equity ratio of 68.545, which may pose risks in a volatile market.
- Net income for the latest quarter was -$17.74 million, indicating ongoing financial challenges.
- Operating margin remains negative at -13.3%, reflecting struggles to achieve profitability.
Fundamentals
| Market cap | $2.02B | Enterprise value | $2.05B | Trailing P/E | — | Forward P/E | 56.51 |
| PEG | — | Price / book | 8.27 | Beta | 1.97 | Dividend yield | 0.00% |
| Revenue growth | 11.4% | Earnings growth | — | Gross margin | 69.4% | Operating margin | -15.2% |
| Profit margin | -23.4% | ROE | -40.8% | ROA | -7.9% | Debt / equity | 0.69 |
| Current ratio | 3.30 | Free cash flow | -$47.50M | Analyst recommendation | strong_buy | Mean target | $93.50 |
| 52w high | $170.87 | 52w low | $32.21 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $114M | $102M | $121M | $117M | $103M | — |
| Op margin | -13.3% | -25.6% | -11.8% | -2.8% | 8.8% | — |
| Net income | -$17.7M | -$63.3M | -$17.7M | -$7.6M | $10.8M | — |
| Gross margin | 68.4% | 66.7% | 69.6% | 72.4% | 69.0% | — |
| Gross profit | $78.2M | $68.2M | $84.3M | $84.5M | $70.9M | — |
| Operating income | -$15.2M | -$26.2M | -$14.2M | -$3.3M | $9.0M | — |
- Revenue +12% vs prior quarter ($114M vs $102M).
- Gross margin 68.4% (was 66.7% prior quarter).
- Operating margin expanded to -13.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $428M | $305M | $203M | $235M | — |
| Op margin | -3.1% | -7.6% | -84.0% | -194.9% | — |
| Net income | -$21.0M | -$52.3M | -$176M | -$549M | — |
| Gross margin | 69.7% | 63.6% | 44.4% | -11.4% | — |
| Gross profit | $298M | $194M | $90.0M | -$26.8M | — |
| Operating income | -$13.1M | -$23.2M | -$170M | -$458M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
2026-10-07 · Encompass Health Expands Rehab Footprint With New Maine Hospital
2026-10-07 · GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
2026-10-02 · GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
2026-09-24 · GeneDx Stock Is Down 30% In Last 1 Year, Can It Climb Again in 2027?
2026-09-09 · GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
2026-09-08 · 3 Promising Genomics Stocks in the Spotlight in 2026
2026-09-01 · GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
2026-08-24 · Top Stock Picks for Week of August 24, 2026
2026-08-19 · Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
Price (daily)
Full chart · RSI · MACD · patterns